Long-term follow-up shows avapritinib effectively manages disease in chronic systemic mastocytosis, indicating its viability as a treatment option.
Long-term follow-up (median, ∼3 years) demonstrates that avapritinib is effective and well tolerated. Avapritinib shows a favorable benefit-risk profile as a chronic ISM treatment.
No takes yet. Share an insight, caveat, or question.
Akin et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: